Keyword: Otsuka Pharmaceutical

Astellas tapped Adaptimmune to develop T-cell therapies. Ireland hit Takeda with an unexpected Shire tax bill. PD-1 med Tyvyt hit its goal in NSCLC.

Avanir is laying off 140 employees, a WARN notice in California shows, shortly after its $116 million Nuedexta marketing settlement with the feds.

Taiho, Otsuka and Chugai wins KRAS-focused licensing deals. Biocon Biologics nabs PE funding before planned IPO. Mark Alles joins Antengene's board.

Avanir pays $116 million in Neudexta kickback suits; China unveils results for a procurement scheme; Aurobindo founder faces insider trading fine.

Avanir has reached a settlement with the feds over a yearslong marketing and kickbacks probe for Nuedexta.

Acadia Pharmaceuticals had to defend its Nuplazid safety last year, and now the drugmaker faces a DOJ probe into its marketing.

AZ's China sales jumped 25% in 2018; Pfizer Japan recalls valsartan drugs made with Mylan's API; resistance might hurt Shionogi and Roche's Xofluza.

More than a year after CNN's exposé about Avanir's Neudexta marketing, the company is nearing a settlement with U.S. officials.

Antengene collects $120 million in series B; Otsuka inks new digital-pill pact; MabSpace merges with HJB.

Allegations in nearly a dozen kickbacks lawsuits against top pharma companies are unfounded, the government said.